Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 6 Capecitabine 6 Fluorouracil 5 Leucovorin 4 pembrolizumab 3 cemiplimab 3 Paclitaxel 3 Cisplatin 3 zolbetuximab 2 trastuzumab deruxtecan 2 fludarabine 2 Trastuzumab 2 Ramucirumab 2 Cyclophosphamide 2 tucatinib 1 repotrectinib 1 paricalcitol 1 enzalutamide 1 durvalumab 1 atezolizumab 1 alpha-2'-deoxythioguanosine 1 aldesleukin 1 Vinorelbine 1 Transurethral Resection of Prostate 1 Taxes 1 Radiosurgery 1 Radiofrequency Ablation 1 Radiation 1 Positron-Emission Tomography 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × paricalcitol × 30 days × Clear all

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

34 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡